Translational Neuro-Oncology Research refers to the process of applying discoveries from basic neuroscience and oncology research to clinical applications for brain and spinal cord tumors. It bridges the gap between laboratory findings and patient care by developing new diagnostic tools, treatment strategies, and personalized therapies.
Identifying genetic mutations and molecular pathways involved in gliomas, medulloblastomas, and other CNS tumors.
Next-generation sequencing (NGS) and liquid biopsy are used for tumor characterization.
Development of small-molecule inhibitors targeting pathways like EGFR, IDH1, and BRAF mutations.
Advances in CAR-T cell therapy and checkpoint inhibitors for glioblastoma and other aggressive brain tumors.
Understanding the blood-brain barrier (BBB) and strategies to enhance drug delivery (e.g., focused ultrasound, nanoparticles).
Studying the role of hypoxia, immune suppression, and glioma stem cells in tumor progression.
Integration of MRI spectroscopy, PET imaging, and AI-driven radiomics for tumor detection and monitoring.
Identification of biomarkers for early diagnosis and treatment response.
Use of patient-derived xenografts (PDX) and organoids to test new drugs.
Adaptive trial designs for rapid assessment of novel therapies.